Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
Vermeulen JN, Lange JM, Tyring SK, Peters PH, Nunez M, Poland G, Levin MJ, Freeman C, Chalikonda I, Li J, Smith JG, Caulfield MJ, Stek JE, Chan IS, Vessey R, Schödel FP, Annunziato PW, Schlienger K, Silber JL. Vermeulen JN, et al. Among authors: chalikonda i. Vaccine. 2012 Jan 20;30(5):904-10. doi: 10.1016/j.vaccine.2011.11.096. Epub 2011 Dec 7. Vaccine. 2012. PMID: 22154769 Clinical Trial.
Diurnal variation of the human adipose transcriptome and the link to metabolic disease.
Loboda A, Kraft WK, Fine B, Joseph J, Nebozhyn M, Zhang C, He Y, Yang X, Wright C, Morris M, Chalikonda I, Ferguson M, Emilsson V, Leonardson A, Lamb J, Dai H, Schadt E, Greenberg HE, Lum PY. Loboda A, et al. Among authors: chalikonda i. BMC Med Genomics. 2009 Feb 9;2:7. doi: 10.1186/1755-8794-2-7. BMC Med Genomics. 2009. PMID: 19203388 Free PMC article.
Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age.
Diaz C, Dentico P, Gonzalez R, Mendez RG, Cinquetti S, Barben JL, Harmon A, Chalikonda I, Smith JG, Stek JE, Robertson A, Caulfield MJ, Biasio LR, Silber JL, Chan CY, Vessey R, Sadoff J, Chan IS, Matthews H, Wang W, Schlienger K, Schödel FP; Protocol 049 Study Group. Diaz C, et al. Among authors: chalikonda i. Vaccine. 2006 Nov 17;24(47-48):6875-85. doi: 10.1016/j.vaccine.2006.06.030. Epub 2006 Jul 7. Vaccine. 2006. PMID: 17050042 Clinical Trial.
Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine.
Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, Shaw A, Silber JL, Schlienger K, Chalikonda I, Vessey SJ, Caulfield MJ. Levin MJ, et al. Among authors: chalikonda i. J Infect Dis. 2003 Nov 1;188(9):1336-44. doi: 10.1086/379048. Epub 2003 Oct 17. J Infect Dis. 2003. PMID: 14593591
Measurement of cell-mediated immunity with a Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization.
Smith JG, Levin M, Vessey R, Chan IS, Hayward AR, Liu X, Kaufhold RM, Clair J, Chalikonda I, Chan C, Bernard M, Wang WW, Keller P, Caulfield MJ. Smith JG, et al. Among authors: chalikonda i. J Med Virol. 2003;70 Suppl 1:S38-41. doi: 10.1002/jmv.10318. J Med Virol. 2003. PMID: 12627485